financetom
Business
financetom
/
Business
/
Selena Gomez relieved focus on Cannes entry 'Emilia Perez,' not personal life
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Selena Gomez relieved focus on Cannes entry 'Emilia Perez,' not personal life
May 19, 2024 1:22 PM

CANNES, France, May 19 (Reuters) - Selena Gomez said

that she was relieved focus had shifted to her role in the new

Mexican cartel musical "Emilia Perez" rather than her personal

life, the singer told Reuters on Sunday.

"It's a relief. I'd rather somebody say I did a terrible job

than talk about my personal life. So, I feel very proud," Gomez

said at the Cannes Film Festival a day after the premiere of the

film, which received a standing ovation for nine minutes.

The former Disney star added that she made up just a small

part of the "incredible masterpiece" that is "Emilia Perez,"

which also stars Zoe Saldana and Karla Sofia Gascon.

The film directed by Jacques Audiard about a Mexican drug

lord who transitions from male to female and starts a nonprofit

dedicated to finding the bodies of disappeared people, is in the

running for the festival's top prize, the Palme d'Or.

Gomez, who also co-stars with Steve Martin and Martin Short

in the Hulu streaming series "Only Murders in the Building," is

the most-followed woman on Instagram with 428 million followers.

Such a large following puts her life under intense public

scrutiny and generates headlines that speculate about her

personal relationships as well as mental and physical health.

The singer who has posted candidly about having lupus and

bipolar disorder told broadcaster NBC's "Today" show this month

that she has decided to limit comments on her account to only

friends as a way to set boundaries.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Tesla's Top North American Sales Executive Departs Amid Slump, The Wall Street Journal Reports
--Tesla's Top North American Sales Executive Departs Amid Slump, The Wall Street Journal Reports
Jul 15, 2025
10:48 AM EDT, 07/15/2025 (MT Newswires) -- Price: 315.29, Change: -1.61, Percent Change: -0.51 ...
Pegasystems Remains 'Undervalued' as AI Growth Story Gains Traction, Wedbush Says
Pegasystems Remains 'Undervalued' as AI Growth Story Gains Traction, Wedbush Says
Jul 15, 2025
10:47 AM EDT, 07/15/2025 (MT Newswires) -- Pegasystems' ( PEGA ) under-the-radar artificial intelligence play remains undervalued by the Wall Street, said Wedbush in a Tuesday note, adding that it saw confidence in the company to drive profitable growth while its Blueprint software continues to gain traction. Wedbush said its recent checks showed Pega Cloud furthering its conversion cycle acceleration...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Kairos' Phase 2 Prostate Cancer Trial Shows Positive Safety Results; Shares Jump
Kairos' Phase 2 Prostate Cancer Trial Shows Positive Safety Results; Shares Jump
Jul 15, 2025
10:43 AM EDT, 07/15/2025 (MT Newswires) -- Kairos Pharma ( KAPA ) shares were up about 75% in recent Tuesday trading after the company reported positive safety results from an ongoing phase 2 trial of ENV-105 in advanced prostate cancer. The favorable safety profile observed in this Phase 2 study is encouraging, said Chief Executive John Yu. Kairos said interim...
Copyright 2023-2026 - www.financetom.com All Rights Reserved